Low-dose estradiol relieved surgical menopause symptoms in a transgender man on testosterone
A 42-year-old transgender man developed a classic menopausal symptom cluster after bilateral salpingo-oophorectomy: hot flashes several times a day, night sweats, headaches, fatigue, cognitive fog, joint pain, and muscle tightness. The symptoms began after surgery and persisted even though he was already receiving testosterone therapy at physiologic male levels. His course is a sharp reminder that testosterone monotherapy does not always substitute for ovarian estrogen production in the wake of surgical menopause.
The postoperative syndrome was not subtle. He also gained 13.6 kg within 12 months of surgery, most of it during the first 5 months, after gaining only 4 kg over the preceding 8 years on testosterone. Endocrine testing did not identify an alternative driver of the weight gain or vasomotor complaints: thyroid studies, adrenal testing, dexamethasone suppression, and pituitary imaging were unrevealing. Infectious and medication-related causes were also excluded. In parallel, gonadotropins were clearly menopausal, with elevated follicle-stimulating hormone and luteinizing hormone consistent with loss of ovarian function.
His hormone pattern exposed the central problem. Testosterone remained measurable, and estradiol was initially in a male reference range, likely from peripheral aromatization of exogenous testosterone. Yet the vasomotor symptoms continued. After testosterone dosing was reduced and then converted from weekly injections to transdermal gel to reduce peaks and troughs, the headaches persisted and estradiol fell further. A neurologist diagnosed migraine without aura, thought to be worsened by hypoestrogenism after surgical menopause.
One sentence captures the turning point: male-range testosterone did not prevent estrogen-deficiency symptoms.
Low-dose transdermal estradiol was then started at 25 μg/24 h twice weekly, with the explicit goal of easing vasomotor symptoms while avoiding unwanted feminization. The clinicians selected the transdermal route because it carries lower thromboembolic risk than oral estrogen in observational data, and because this patient already had vascular risk factors, including type 1 diabetes, hypertension, and dyslipidemia. After 1 week, he reported only modest improvement, but the direction was encouraging enough to justify dose escalation. The patch was increased to 37.5 μg/24 h twice weekly and then to 50 μg/24 h twice weekly.
By 1 month, the response was clinically meaningful. Hot flashes were nearly gone, cognition improved, energy returned, joint and muscle discomfort eased, and weight stabilized. Estradiol levels remained stable in the months that followed, while testosterone stayed near the lower end of the physiologic cisgender male range. The patient did not report mastalgia, gynecomastia, worsening dysphoria, or thromboembolic events. In a transgender man who valued masculinization, the absence of visible feminizing effects mattered as much as symptom control.
The weight trajectory deserves attention because it may reflect more than symptom relief alone. After estradiol initiation, his weight fell from a postoperative peak of 79.8 kg to about 74.5 kg within 4 months, before he even met with a dietitian. Tirzepatide was later added, and weight fell further to 70.5 kg and then 68.5 kg by the last follow-up. His glycated hemoglobin improved as well, from 7.5% after surgery to 6.9% within a few months of starting the estradiol patch, before tirzepatide was introduced. Those changes cannot be assigned to estradiol alone, but the temporal pattern suggests that untreated hypoestrogenism may have been amplifying fatigue, appetite dysregulation, or impaired metabolic control.
Why estradiol can still matter after testosterone therapy
Current gender-affirming hormone guidance generally supports testosterone monotherapy for most transgender men. That approach works well for many patients, but the assumption that testosterone alone always provides enough peripheral estrogen activity after oophorectomy is too simple. Aromatization of testosterone does generate estradiol, yet the amount is variable and may not restore the hormonal milieu needed to suppress vasomotor symptoms. In practice, estradiol may also be an imperfect surrogate, because peripheral estrogen metabolism is more complex than a single serum value can capture.
The physiology fits the bedside observation. Vasomotor symptoms are driven largely by estrogen withdrawal within hypothalamic thermoregulatory pathways, not by androgen deficiency alone. When ovarian estrogen production disappears abruptly, the central temperature set point becomes unstable, producing hot flashes and night sweats. Testosterone can be converted to estradiol, but the conversion may be insufficient in some individuals, especially after bilateral oophorectomy, when endogenous ovarian contribution is permanently lost. This case shows that a measurable estradiol concentration in the male range does not guarantee symptom control.
Feminization risk, thrombosis, and the case for individualized treatment
Adjunctive estradiol in a transgender man raises predictable concerns about feminization and venous thromboembolism. Those concerns are real, but they are not a reason to dismiss treatment out of hand. Physiologic testosterone appears to protect against clinically obvious breast tissue stimulation, and low-dose transdermal estradiol generally produces lower systemic thrombotic risk than oral formulations. In this patient, the chosen dose remained modest, and no feminizing changes emerged during follow-up.
The thrombotic discussion is especially relevant because surgical menopause may carry broader health consequences beyond hot flashes. In cisgender women, early loss of ovarian function has been associated with cardiovascular disease, accelerated bone loss, and possibly earlier cognitive decline. Whether those data apply cleanly to transgender men receiving testosterone after oophorectomy is unknown. Even the ideal estradiol target in this setting is unsettled. Some cisgender female data suggest higher serum estradiol concentrations may support bone health, but there is no validated target for transgender men on testosterone after ovarian removal.
A bedside lesson with real limits
This case supports a practical approach: persistent vasomotor symptoms after oophorectomy should trigger a search for hypoestrogenemia even when testosterone dosing appears adequate. Low-dose transdermal estradiol can be an effective rescue strategy, and it may do so without undermining gender affirmation when used carefully and monitored closely. The patient’s symptom response, metabolic improvement, and absence of visible feminization all argue for symptom-guided treatment rather than rigid adherence to testosterone monotherapy.
The evidence base remains thin. One case does not define a standard, and the long-term skeletal, cardiovascular, and cognitive effects of adding estradiol to testosterone in transgender men have not been established. More longitudinal data are needed before clinicians can say how much estrogen is enough, how long it should be given, and which patients are most likely to benefit without added risk.